PHILADELPHIA, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Research published in Nature Medicine and Journal of Hepatology by scientists at the National Institutes of Health using JD-5037, the best-in-class peripheral CB1 inverse agonist from Jenrin Discovery, LLC has illuminated the mechanism of action for this class of drugs, providing a rationale for the potential therapeutic benefits seen when only peripheral endocannabinoid receptors are inhibited.
Help employers find you! Check out all the jobs and post your resume.
